Curated News
By: NewsRamp Editorial Staff
April 30, 2026

BioVersys AG Shareholders Approve All Board Proposals at AGM

Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • BioVersys shareholders approved all board proposals, ensuring continued focus on Phase 3 trial for BV100 against MDR bacteria.
  • BioVersys AG held its AGM, reelecting board members and approving financial reports, supporting its pipeline of antibacterial products.
  • BioVersys advances treatments for life-threatening infections from multi-drug resistant bacteria, aiming to save lives worldwide.
  • BioVersys progresses alpibectir in Phase 2 for tuberculosis, collaborating with GSK and the University of Lille.

Impact - Why it Matters

This news matters because BioVersys is advancing critical treatments for drug-resistant infections, a growing global health crisis. With Phase 3 trials underway for BV100 and Phase 2 for alpibectir, the company is on the frontline of developing new antibiotics against superbugs. Shareholder approval ensures continued funding and strategic direction, potentially bringing life-saving therapies to patients with limited options. For investors and healthcare professionals, this signals progress in addressing antimicrobial resistance, a top WHO priority.

Summary

BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company combating multi-drug resistant (MDR) bacterial infections, announced that shareholders approved all proposals at its Annual General Meeting (AGM). Key outcomes included the re-election of Dr. Seng Chin Mah as Chairman and the election of Ms. Simona Skerjanec to the Board of Directors. The company highlighted its progress, including the first patient first visit (FPFV) for the global Phase 3 trial of BV100, a candidate targeting Acinetobacter baumannii infections. Shareholders also approved the 2025 Annual Report, financial statements, and compensation packages for the Board and Executive Committee.

The company’s pipeline includes alpibectir for tuberculosis (Phase 2, in collaboration with GlaxoSmithKline) and preclinical programs leveraging its TRIC and Ansamycin Chemistry platforms. BioVersys focuses on overcoming resistance mechanisms and addressing unmet medical needs in serious infections. The full AGM documents are available on the company’s website, including the Annual Report and AGM details. Dr. Seng Chin Mah expressed gratitude for shareholder trust and emphasized the team's focus on delivering therapies to patients in dire need.

This news underscores BioVersys's commitment to advancing novel antibacterials against MDR pathogens, a critical global health threat. With BV100 in Phase 3 and alpibectir progressing, the company is poised to address severe nosocomial infections and tuberculosis. The board changes bring fresh expertise, while the strong shareholder support enables continued investment in the pipeline. For more details, view the original release on www.newmediawire.com.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, BioVersys AG Shareholders Approve All Board Proposals at AGM

blockchain registration record for this content.